超声BI-RADS 3级乳腺小肿块联合TR活性检测的应用分析

Application of ultrasound combined with thioredoxin reductase detection in BI-RADS 3 small breast nodules

目的探讨乳腺超声联合硫氧还蛋白还原酶(TR)活性检测在提高BI-RADS 3级乳腺小肿块恶性病检出的应用价值。方法选取2015年1月—2016年1月湖北医药学院附属人民医院健康管理中心乳腺超声检查确诊BI-RADS 3级乳腺肿块(直径≤2 cm),同时TR活性检测结果异常,并行活检的被检者102例作为观察组,同期随机选取未行TR活性检测,仅行活检的被检者110例作为对照组。对比分析两组被检者一般资料及术后乳腺恶性病检出率的差异。结果两组在是否绝经、月经初潮年龄、不同活检方法等方面差异无统计学意义(P>0.05)。观察组TR活性检测结果阳性比例与观察组术后病理阳性比例间具有较好的一致性。观察组术后病理良性病变比例(92.4%)与对照组比较(93.5%),差异无统计学意义(P>0.05)。观察组术后病理阳性率(8.9%)高于对照组(1.8%)(P<0.05)。结论超声BI-RADS 3级乳腺小肿块(≤2 cm)联合TR活性检测,可筛查出部分潜在高危被检者,提高乳腺恶性病(乳腺癌)的检出率,值得临床推广、应用。

Objective This study investigated the application value of ultrasound combined with thioredoxin reductase detection for the detection of breast malignant lesions in BI-RADS category 3 nodules(≤2 cm).Methods Physical examiners with ultrasound BI-RADS category 3 nodules(≤2 cm)treated in affiliated Dongfeng Hospital from Jan.2015 to Jan.2016,including 102 cases underwent breast ultrasound combined with thioredoxin reductase detection(observation group)and 110 cases underwent breast ultrasound only(control group)were collected.All 212 cases were diagnosed by pathological examination to compare the clinical characteristics and the detection rate of malignant lesions between two groups.Results There were no significant difference between two groups in menstrual condition,age of menarche and biopsy methods(all P>0.05).The positive rate of thioredoxin reductase detection is positively correlated with the positive rate of pathology for BI-RADS category 3 nodules in observed group.The rate of benign lesions between observed group(92.4%)and control group(93.5%)was no significant difference(P>0.05).The rate of malignant lesions in observed group(8.9%)was obviously higher than the control group(1.8%)(P<0.05).Conclusion The breast ultrasound BI-RADS category 3 nodules(≤2 cm)combined with thioredoxin reductase detection is valuable for improving the positive rate of malignant lesions in BI-RADS category 3 breast nodules,which is worthy of clinical application.